Case Report: Suspected Hyperacute Rejection During Living Kidney Transplantation

Transplant Proc. 2023 May;55(4):1089-1091. doi: 10.1016/j.transproceed.2023.04.020. Epub 2023 May 4.

Abstract

Background: We report a case of suspected hyperacute rejection during living kidney transplantation.

Case report: A 61-year-old man underwent kidney transplantation in November 2019. Before the transplantation, immunologic tests revealed the presence of anti-HLA antibodies but not donor-specific HLA antibodies. The patient was intravenously administered 500 mg of methylprednisolone (MP) and basiliximab before perioperative blood flow reperfusion. After blood flow restoration, the transplanted kidney turned bright red and then blue. Hyperacute rejection was suspected. After the intravenous administration of 500 mg of MP and 30 g of intravenous immunoglobulin, the transplanted kidney gradually changed from blue to bright red. The initial postoperative urine output was good. On the 22nd day after the renal transplantation, the patient was discharged with a serum creatinine level of 2.38 mg/dL, and the function of the transplanted kidney gradually improved.

Conclusions: In this study, non-HLA antibodies may have been a cause of the hyperacute rejection, which was managed with additional perioperative therapies.

Publication types

  • Case Reports

MeSH terms

  • Antibodies
  • Graft Rejection
  • Humans
  • Immunoglobulins, Intravenous
  • Kidney
  • Kidney Transplantation* / adverse effects
  • Male
  • Methylprednisolone / therapeutic use
  • Middle Aged

Substances

  • Antibodies
  • Immunoglobulins, Intravenous
  • Methylprednisolone